These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25431338)

  • 1. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis.
    Luo KW; Yue GG; Ko CH; Gao S; Lee JK; Li G; Fung KP; Leung PC; Lau CB
    Oncol Rep; 2015 Jul; 34(1):477-87. PubMed ID: 25998578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models.
    Luo KW; Ko CH; Yue GG; Lee MY; Siu WS; Lee JK; Shum WT; Fung KP; Leung PC; Li G; Evdokiou A; Lau CB
    Cancer Lett; 2013 Oct; 339(1):42-8. PubMed ID: 23896464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model.
    Ko CH; Yue GG; Gao S; Luo KW; Siu WS; Shum WT; Shiu HT; Lee JK; Li G; Leung PC; Evdokiou A; Lau CB
    J Ethnopharmacol; 2017 May; 204():77-85. PubMed ID: 28412218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
    J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Green tea (Camellia sinensis) extract inhibits both the metastasis and osteolytic components of mammary cancer 4T1 lesions in mice.
    Luo KW; Ko CH; Yue GG; Lee JK; Li KK; Lee M; Li G; Fung KP; Leung PC; Lau CB
    J Nutr Biochem; 2014 Apr; 25(4):395-403. PubMed ID: 24561153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
    Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
    Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
    Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
    Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
    Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
    Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
    Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
    Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
    Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
    Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
    Labrinidis A; Hay S; Liapis V; Findlay DM; Evdokiou A
    Int J Cancer; 2010 Jul; 127(2):345-54. PubMed ID: 19924813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
    Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F
    BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence-guided surgery of prostate cancer bone metastasis.
    Miwa S; Matsumoto Y; Hiroshima Y; Yano S; Uehara F; Yamamoto M; Zhang Y; Kimura H; Hayashi K; Yamamoto N; Bouvet M; Sugimoto N; Tsuchiya H; Hoffman RM
    J Surg Res; 2014 Nov; 192(1):124-33. PubMed ID: 24972740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
    Misso G; Porru M; Stoppacciaro A; Castellano M; De Cicco F; Leonetti C; Santini D; Caraglia M
    Cancer Biol Ther; 2012 Dec; 13(14):1491-500. PubMed ID: 22990205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.